Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release

Department of Neurosurgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 10/2010; 107(42):18143-8. DOI: 10.1073/pnas.1003919107
Source: PubMed

ABSTRACT Effective treatment of brain neurological disorders such as Alzheimer's disease, multiple sclerosis, or tumors should be possible with drug delivery through blood-brain barrier (BBB) or blood-brain tumor barrier (BTB) and targeting specific types of brain cells with drug release into the cell cytoplasm. A polymeric nanobioconjugate drug based on biodegradable, nontoxic, and nonimmunogenic polymalic acid as a universal delivery nanoplatform was used for design and synthesis of nanomedicine drug for i.v. treatment of brain tumors. The polymeric drug passes through the BTB and tumor cell membrane using tandem monoclonal antibodies targeting the BTB and tumor cells. The next step for polymeric drug action was inhibition of tumor angiogenesis by specifically blocking the synthesis of a tumor neovascular trimer protein, laminin-411, by attached antisense oligonucleotides (AONs). The AONs were released into the target cell cytoplasm via pH-activated trileucine, an endosomal escape moiety. Drug delivery to the brain tumor and the release mechanism were both studied for this nanobiopolymer. Introduction of a trileucine endosome escape unit resulted in significantly increased AON delivery to tumor cells, inhibition of laminin-411 synthesis in vitro and in vivo, specific accumulation in brain tumors, and suppression of intracranial glioma growth compared with pH-independent leucine ester. The availability of a systemically active polymeric drug delivery system that passes through the BTB, targets tumor cells, and inhibits glioma growth gives hope for a successful strategy of glioma treatment. This delivery system with drug release into the brain-specific cell type could be useful for treatment of various brain pathologies.

Download full-text


Available from: Eggehard Holler, Aug 19, 2015
1 Follower
  • Source
    • "We postulated that introduction of a CPP (Regberg et al. 2013) into the Cas9 protein might enable its direct delivery into cells. However , when we genetically fused Cas9 to a CPP that consists of four Gly, nine Arg, and four Leu (Matsui et al. 2003; Ding et al. 2010), it was difficult to obtain purified protein in suitable quantities, which is in line with results with ZFNs (Gaj et al. 2012) and TALENs (Liu et al. 2014) fused with several CPPs. Thus, we sought to minimize genetic modification of Cas9 by adding a Cys residue at the C terminus (Fig. 1) to enable CPP conjugation after Cas9 expression. "
    [Show abstract] [Hide abstract]
    ABSTRACT: RNA-guided endonucleases (RGENs) derived from the CRISPR/Cas system represent an efficient tool for genome editing. RGENs consist of two components: Cas9 protein and guide RNA. Plasmid-mediated delivery of these components into cells can result in uncontrolled integration of the plasmid sequence into the host genome and unwanted immune responses and potential safety problems that can be caused by the bacterial sequences, and requires transfection tools for mediating the delivery. Here we show that simple treatment with cell-penetrating peptide (CPP)-conjugated recombinant Cas9 protein and CPP-complexed guide RNAs lead to endogenous gene disruptions in human cell lines. The Cas9 protein was conjugated to CPP via a thioether bond, whereas the guide RNA was complexed with CPP, forming condensed, positively charged nanoparticles. Simultaneous and sequential treatment of human cells, including embryonic stem cells, dermal fibroblasts, HEK293T cells, HeLa cells, and embryonic carcinoma cells, with the modified Cas9 and guide RNA leads to efficient gene disruptions with reduced off-target mutations relative to plasmid transfections, resulting in the generation of clones containing RGEN-induced mutations. Our CPP-mediated RGEN delivery process provides a plasmid-free and additional transfection reagent-free way to use this tool with reduced off-target effects. We envision that our method will facilitate RGEN-directed genome editing.
    Genome Research 04/2014; 24(6). DOI:10.1101/gr.171264.113 · 13.85 Impact Factor
  • Source
    • "PMLA was originally synthesized for applications in the biomedical field. Moreover, PMLA has been successfully used as platform in the synthesis of nanovectors (Abdellaoui et al., 1998;Osanai and Nakamura, 2000; Cammas et al., 2000; Cammas-Marion and Guérin, 2000; Martinez Barbosa et al., 2004) or as a constituent in macromolecular conjugates bearing several functionalities to treat human brain and breast tumors in mouse models (Fujita et al., 2006, 2007; Ljubimova et al., 2008; Ding et al., 2010). In all of these investigations it has been concluded that PMLA was a promising building block for the design of efficient drug delivery systems. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Design of an efficient site-specific drug delivery system based on degradable functional polymers still remains challenging. In this work, we synthesized and characterized three degradable functional polyesters belonging to the poly(malic acid) family: the poly(benzyl malate) (PMLABe), the poly(ethylene glycol)-b-poly(benzyl malate) (PEG(42)-b-PMLABe), the biotin-poly(ethylene glycol)-b-poly(benzyl malate) (Biot-PEG(62)-PMLABe). Starting from these building blocks, we were able to prepare the corresponding well-defined degradable functional nanoparticles whose toxicity was evaluated in vitro on normal and cancer cell lines. Results have evidenced that the prepared nanoparticles did not show any significant cytotoxicity even at high concentrations. A model anti-cancer drug (doxorubicin, Dox) or a fluorescent probe (1,1'-dioctadecyl-3,3,3',3'-tetramethylindodicarbocyanine, DiD oil) has been encapsulated into PMLABe, PEG(42)-PMLABe or Biot-PEG(62)-PMLABe based nanoparticles in order to evaluate, respectively, the in vitro cytotoxicity of Dox-loaded nanoparticles on normal and cancer cell lines and the ligand (biotin) effect on cellular uptake in vitro using mmt 060562 cell line. Dox-loaded PMLABe, PEG(42)-PMLABe or Biot-PEG(62)-PMLABe nanoparticles showed an in vitro cytotoxicity similar to that of free Dox. Moreover, the DiD oil loaded Biot-PEG(62)-PMLABe based nanoparticles showed a better in vitro cellular uptake than ligand-free DiD oil loaded nanoparticles. Both results evidence the great potential of such degradable functional poly(malic acid) derivatives for the design of highly efficient site-specific anti-cancer nanovectors.
    International Journal of Pharmaceutics 04/2011; 423(1):84-92. DOI:10.1016/j.ijpharm.2011.04.035 · 3.65 Impact Factor
  • dressNature Reviews Drug Discovery 11/2010; 9(12):917. DOI:10.1038/nrd3332 · 37.23 Impact Factor
Show more